Economic and Clinical Benefits of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV in Infants: A Cost-Effectiveness Analysis for Mexico
Background/Objectives: Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in children. A novel RSVpreF vaccine for use among pregnant women for the prevention of RSV in infants is expected to be licensed in Mexico. Hence, the clinical and economic burden of RSV among infa...
Saved in:
Main Authors: | José Luis Huerta, Robyn Kendall, Luka Ivkovic, Carlos Molina, Amy W. Law, Diana Mendes |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/13/1/77 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
by: Alexander Domnich, et al.
Published: (2025-01-01) -
Favorable Nonclinical Safety Profile of RSVpreF Bivalent Vaccine in Rats and Rabbits
by: Jun Zhou, et al.
Published: (2024-12-01) -
Prevention of respiratory syncytial virus infection in children. Recommendations of the Polish Society of Paediatrics and the National Paediatric Consultant
by: Teresa Jackowska, et al.
Published: (2024-12-01) -
Relationship between RSV-hospitalized children and meteorological factors: a time series analysis from 2017 to 2023
by: Shuying Wang, et al.
Published: (2025-02-01) -
Anti-Idiotypic Antibody as a Booster Vaccine Against Respiratory Syncytial Virus
by: Shreya Mukhopadhyay, et al.
Published: (2025-01-01)